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OBJECTIVE — To provide a simple clinical diabetes risk score and to identify characteristics
that predict later diabetes using variables available in the clinic setting as well as biological
variables and polymorphisms.
RESEARCH DESIGN AND METHODS — Incident diabetes was studied in 1,863 men
and 1,954 women, 30–65 years of age at baseline, with diabetes deﬁned by treatment or by
fasting plasma glucose 7.0 mmol/l at 3-yearly examinations over 9 years. Sex-speciﬁc logistic
regression equations were used to select variables for prediction.
RESULTS — A total of 140 men and 63 women developed diabetes. The predictive clinical
variables were waist circumference and hypertension in both sexes, smoking in men, and dia-
betes in the family in women. Discrimination, as measured by the area under the receiver
operating curves (AROCs), were 0.713 for men and 0.827 for women, a little higher than for the
FinishDiabetesRisk(FINDRISC)score,withfewervariablesinthescore.Combiningclinicaland
biological variables, the predictive equation included fasting glucose, waist circumference,
smoking,and-glutamyltransferaseformenandfastingglucose,BMI,triglycerides,anddiabetes
in family for women. The number of TCF7L2 and IL6 deleterious alleles was predictive in both
sexes, but after including the above clinical and biological variables, this variable was only
predictive in women (P  0.03) and the AROC statistics increased only marginally.
CONCLUSIONS — The best clinical predictor of diabetes is adiposity, and baseline glucose
is the best biological predictor. Clinical and biological predictors differed marginally between
men and women. The genetic polymorphisms added little to the prediction of diabetes.
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A
numberofdiabetesriskscoreshave
beendevelopedtodetectthosewho
should be screened for diabetes (1).
In the Data from an Epidemiological Study
on the Insulin Resistance Syndrome
(DESIR)cohort,wehavepreviouslystudied
the anthropometric variables associated
with diabetic levels of fasting glucose and
found that BMI, waist circumference, and
waist-to-hip ratio were equally useful in the
identiﬁcation of individuals with undiag-
nosed diabetes (2).
The ﬁrst score to identify lifestyle and
clinical parameters predictive of later di-
abetes was developed by Lindstro ¨m and
Tuomilehto (3), from a population-based
sampleofpeoplewhorespondedtoques-
tionnaires in 1987; 10-year incident dia-
betes was identiﬁed from a registry of
diabetes treatment. A similar Finnish Di-
abetes Risk Score (FINDRISC) was used
in a cross-sectional study (4). In the
American Atherosclerosis Risk in Com-
munities (ARIC) study and in a Thai pop-
ulation, predictive risk factors were also
identiﬁed, wherein diabetes was deﬁned
by treatment or diabetic levels of fasting
and 2-h glucose from an oral glucose tol-
erancetest(5,6).Morerecently,Simmons
et al. (7) published a score from the Eu-
ropean Prospective Investigation into
Cancer Study (EPIC)-Norfolk study,
wherein incident diabetes was deﬁned by
clinical identiﬁcation of diabetes or A1C
7% and dietary factors and physical ac-
tivity were included. Finally, dietary and
other noninvasive factors associated with
5-year incident, self-reported cases of di-
abetes were identiﬁed in the large EPIC-
Potsdam study (8).
In the San Antonio Study, Stern et al.
(9) published a score based on prospec-
tive clinical and biological data. In the
Framingham cohort, four scores were
proposed:aclinicalscoreandthreescores
with both clinical and biological factors
with incident diabetes identiﬁed at fol-
low-up by diabetic treatment and/or fast-
ing glucose levels (10). Other studies on
diabetes risk factors include one in
Frenchmenwithimpairedfastingglucose
(6.1–6.9 mmol/l), which identiﬁed life-
style and clinical and biological factors
predictive of diabetes (11).
As risk scores cannot always be gen-
eralized from one country to another
(12,13), the aim of this study was to de-
scribesex-speciﬁclifestyleandclinicaldi-
abetes risk factors in a French population
followed over 9 years in order to aid in
identifying those at risk for incident dia-
betes. Additional aims were to study the
impact of biological factors and genetic
polymorphisms in predicting diabetes.
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METHODS— The study population
consistedofmenandwomenaged30–64
years who participated in the 9-year fol-
low-up study, DESIR. Participants were
recruited from volunteers who were of-
fered periodic health examinations free of
chargebytheFrenchSocialSecurityat10
health examination centers in western
France. All subjects provided informed
written consent, and the protocol was ap-
proved by an ethics committee.
Incident cases of diabetes were iden-
tiﬁedbytreatmentfordiabetesorafasting
plasmaglucose7.0mmol/latoneofthe
3-yearly examinations; after exclusion of
individuals with diabetes at baseline and
thosewithunknowndiabetesstatusatthe
9-year examination, 1,863 men and
1,954 women with glucose, BMI, and
waistcircumferencemeasuresavailableat
baseline were included in the study.
Two measures of blood pressure, us-
ing a mercury sphygmomanometer, and
heart rate were taken in a supine position
after 5 min of rest, and mean values were
usedforanalyses.Weightandheightwere
measured in lightly clad participants, and
BMIwascalculated.Waistcircumference,
the smallest circumference between the
lower ribs and the iliac crest, was also
measured.
The examining physician noted the
family history of diabetes and meno-
pausal status in a clinical questionnaire;
treatment for diabetes and hypertension
and lipids were recorded. Hypertension
was deﬁned by systolic/diastolic blood
pressure of at least 140/90 mmHg or be-
ing on antihypertensive medication.
Smoking habits, alcohol consumption
(glasses of wine, beer, cider, and spirits per
day), and degree of physical activity (at
home, at work, and sport) were assessed
using a self-administered questionnaire.
All biochemical measurements were
from one of four health center laborato-
ries located in France at Blois, Chartres,
LA Riche, or Orle ´ans. Fasting plasma glu-
cose, measured by the glucose oxidase
method, was applied to ﬂuoro-oxalated
plasma using a Technicon RA100 (Bayer
Diagnostics, Puteaux, France) or a Spe-
ciﬁc or a Delta device (Konelab, Evry,
France). Total cholesterol, HDL choles-
terol, triglycerides, alanine aminotrans-
ferase (ALT), -glutamyltransferase
(GGT), and creatinine were assayed by
DAX 24 (Bayer Diagnostics) or KONE
(Konelab). Insulin was quantiﬁed by
Table 1—Clinical and biological characteristics at baseline of men and women with and without incident diabetes during the 9 years of the
DESIR study
Men Women
P for
variable
P for
interaction
with sex Diabetes No diabetes P* Diabetes No diabetes P*
n 140 1,723 63 1,891
Age (years) 50  94 7  10 0.0001 52  84 7  10 0.0005 0.0001† 0.6
Diabetes in the family 28 (20) 312 (18) 0.6 27 (43) 368 (19) 0.0001 ‡ 0.003
Current smoker 52 (37) 418 (24) 0.0009 10 (16) 249 (13) 0.5 0.001† 0.3
Alcohol intake (g/day)§ 34  32 23  22 0.005 8  11 7  11 0.5 0.006† 0.2
Physical activity
Little 43 (31) 422 (24) 22 (35) 465 (25)
Moderate 72 (51) 911 (53) 0.07 33 (52) 1036 (55) 0.04 0.03† 0.7
Intensive 25 (18) 388 (23) 8 (13) 386 (20)
Waist circumference (cm) 96  10 89  9 0.0001 90  12 76  10 0.0001 0.0001† 0.3
BMI (kg/m²)§ 27.5  4.0 25.1  3.0 0.0001 29.2  5.1 23.7  3.8 0.0001 0.0001† 0.3
Menopause 30 (48) 718 (38) 0.1
Large baby, birth weight
4k g
16 (27) 284 (15) 0.02
Hypertension 87 (62) 678 (39) 0.0001 39 (62) 527 (28) 0.0001 0.0001 0.1
Heart rate (min) 68  10 66  10 0.007 71  11 68  9 0.02 0.0005† 0.7
Treatment for lipids 20 (14) 126 (7) 0.004 9 (14) 129 (7) 0.03 0.0003† 0.9
Fasting glucose (mmol/l)§ 6.05  0.55 5.39  0.49 0.0001 5.96  0.58 5.11  0.46 0.0001 0.0001† 0.1
GGT (IU/l)§ 64.3  67.2 39.5  38.3 0.0001 36.4  33.6 21.7  21.2 0.0001 0.0001† 0.4
ALT (UI/l)§ 41.7  28.3 30.3  18.1 0.0001 28.9  22.2 20.1  13.8 0.0001 0.0001† 0.4
Triglycerides (mmol/l)§ 1.79  1.45 1.26  0.80 0.0001 1.50  0.78 0.93  0.50 0.0001 ‡ 0.006
HDL cholesterol (mmol/l) 1.41  0.37 1.50  0.38 0.01 1.53  0.34 1.80  0.42 0.0001 ‡ 0.008
Total cholesterol (mmol/l) 6.06  1.05 5.82  0.97 0.009 5.94  1.04 5.61  0.96 0.02 0.0001† 0.6
Creatinine (mol/l) 91.0  13.9 89.1  11.1 0.06 77.1  10.7 74.1  10.0 0.02 0.006† 0.4
White blood cell count
(10
9/l)§
6.9  2.1 6.4  1.7 0.002 7.3  4.0 6.2  1.6 0.0002 0.0001† 0.2
n 135 1,617 61 1,782
Number of TCF7L2 and
IL6 deleterious
alleles
2.0 1.8 0.008 2.2 1.8 0.03 0.0007 0.7
DataaremeansSDandn(%)unlessotherwiseindicated.*Pcomparingmeansandpercentagesbytand²tests.†Pforvariableinlogisticmodelwithonlyvariable
and sex, as interaction not signiﬁcant. ‡P for variable not given, as the interaction is signiﬁcant. §Log transformation because of a nonsymmetric distribution.
Hypertension: systolic/diastolic blood pressure 140/90 mmHg or medication for hypertension.
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with an automated analyzer (IMX; Ab-
bott, Rungis, France). White cell counts
were determined by a Technicon H* or
Technicon H3RTX (Bayer Diagnostics),
a JT2 (Beckman/Coulter, Roissy,
France), or an Argos (ABX, Montpellier,
France). Interlaboratory variability was
assessed monthly on normal and patho-
logical values for each biologic variable.
Single nucleotide polymorphism
(SNP) genotyping was performed with
SNPlex Technology (Applied Biosystems,
FosterCity,CA)basedonoligonucleotide
ligation assay combined with multiplex
PCR target ampliﬁcation (http://www.
appliedbiosystems.com) (14).
Statistical methods
Statistical analysis was performed using
SASversion9.1(SASInstitute,Cary,NC).
Alcohol intake, BMI, fasting glucose, in-
sulin, ALT, GGT, triglycerides, and white
blood cell count were log-transformed
because of their skewed distributions.
Characteristics of men and women
with and without incident diabetes are
shown as means  SD or n (%) and com-
pared by tor 
2tests or by linear regression
for the polymorphisms with additive mod-
els. The logistic model was used to test for
interactions with sex, and P are reported;
signiﬁcantinteractions(P0.01)provided
the rational for sex-speciﬁc models.
The linearity of continuous parame-
ters in logistic analyses was studied by
adding a squared term and comparing
nestedmodelsbylikelihoodratiotests;all
variables were linearly related with the
logit of diabetes incidence except for fast-
ing glucose (log transformed); in the
models, glucose(log) was centered by
subtracting its mean, and its square was
systematically included.
Parsimonious logistic regression
models were selected using forwards and
backwards as well best model selection
criteria using all parameters; the Hosmer-
Lemeshow goodness-of-ﬁt test was the
principal criteria for selection of a model.
Interactions with sex were tested. The
area under the receiver operating charac-
teristic curve (AROC) for sensitivity-
speciﬁcity quantiﬁed the discrimination
between diabetic and nondiabetic partic-
ipants. Bootstrap sampling was used to
validate the choice of variables in the
models, with 1,000 samples of the same
sizesasthestudypopulations.Thechoice
of variables was also validated in the Cox
model.
To derive a simple clinical score from
the clinical equations, we used the -co-
efﬁcients from the logistic regression
analysis; for waist circumference, four
groups were deﬁned, linearly, from the
approximate sex-speciﬁc quartiles. The
score was validated in two French co-
horts: E3N and SU.VI.MAX (15,16) (on-
line appendix Fig. 1 [available at http://
dx.doi.org/10.2337/dc08-0368]). The
ﬁrst study identiﬁed incident diabetes by
self-questionnaire or treatment reim-
bursement, the second by fasting glucose
or treatment.
Table 2—-Coefﬁcients for the clinical, clinical  biological, and clinical  biological  genetic equations: the DESIR study
Clinical equation
Clinical  biological
equation
Clinical  biological 
genetic equation
n 	 1,860 men (140
with diabetes) and n 	
1,954 women (63 with
diabetes)
n 	 1,860 men (140
with diabetes) and n 	
1,954 women (63 with
diabetes)
n 	 1,655 men (128
with diabetes) and n 	
1,740 women (58 with
diabetes)
 P  P  P
Men
Intercept 
10.45 
10.53 10.91
Current smoker 0.72 0.0002 0.88 0.0001 0.94 0.0001
Waist circumference (cm) 0.081 0.0001 0.060 0.0001 0.060 0.0001
Hypertension* 0.50 0.01
Fasting glucose (mmol/l)† 10.15 0.0001 10.17 0.0001
Fasting glucose²† 24.16 0.002 22.42 0.007
GGT (IU/l)† 0.39 0.01 0.42 0.007
Number of TCF7L2 and IL6 deleterious alleles 0.14 0.2
AROC statistic 0.733 0.850 0.851
Hosmer-Lemeshow ﬁt test 0.7 0.8 0.1
Women
Intercept 
11.81 
18.91 
20.43
Diabetes in the family 1.09 0.0001 0.80 0.01 0.75 0.02
Waist circumference (cm) 0.095 0.0001
BMI (kg/m²)† 4.38 0.0001 4.69 0.0001
Hypertension* 0.64 0.03
Fasting glucose (mmol/l)† 9.66 0.001 9.35 0.001
Fasting glucose²† 23.89 0.06 22.39 0.08
Triglycerides (mmol/l)† 0.95 0.003 0.86 0.01
Number of TCF7L2 amd IL6 deleterious alleles 0.36 0.04
AROC statistic 0.839 0.917 0.912
Hosmer-Lemeshow ﬁt test 0.6 0.9 0.8
*Systolic/diastolic blood pressure 140/90 mmHg or medication for hypertension. †Fasting glucose, GGT, BMI, and triglycerides were log transformed.
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study (glucokinase: GCK-30 G/A
rs1799884, interleukine 6: IL6-174 G/C
rs1800795, and Kir6.2: KCNJ11 E23K
rs5219 and TCF7L2 rs7903146) follow-
ing previous analyses in this population
(14). Additive models discriminated best
betweendiabeticandnondiabeticpeople.
For the two polymorphisms found to be
the most related with incident diabetes
(IL6 and TCF7L2), the number of delete-
rious alleles (as a continuous variable)
was calculated and added as a variable to
the (clinical  biological) equations cho-
senabove.Asthisanalysisaimedtodeter-
mine those who should be screened for
diabetes, we have analyzed all individuals
andhavenotexcludedthosebornoutside
of mainland France. This analysis was on
a smaller population (1,655 men and
1,740 women), where these two poly-
morphisms were available.
We compared our clinical risk score
with the FINDRISC score (3) using the
AROC statistic; FINDRISC includes age,
BMI, waist circumference, antihyperten-
sive medication, physical activity, previ-
ously known high glucose, and daily
consumption of vegetables, and fruits or
berries; we were not able to include the
latter two items. Our (clinical  biologi-
cal) equation was compared with the
Stern equation, including age, sex, fasting
glucose, systolic blood pressure, HDL
cholesterol, BMI, and diabetes in the fam-
ily; we did not include the factor for cod-
ing Mexican Americans (9).
RESULTS— In the DESIR popula-
tion, 140 men and 63 women had inci-
dent diabetes.
Clinical predictors of incident
diabetes
Alloftheclinicalvariablesshowedsimilar
relations with incident diabetes in both
men and women with the exception of
diabetes in the family: noted for 43% of
women with incident diabetes and 19%
without diabetes and for 20 and 18% of
men, respectively (P for sex interaction 	
0.003) (Table 1).
The ﬁrst most predictive variable was
waist circumference, closely followed by
BMI, in both sexes. The selected model in
men included waist circumference,
smoking, and hypertension and in
women included waist circumference, di-
abetes in the family, and hypertension
(Table2).Thesemodelsshowedagoodﬁt
(Hosmer-Lemeshow P 	 0.7 and 0.6 in
men and women, respectively) and well
discriminated the diabetic and nondia-
betic populations (AROC 0.733 and
0.839, respectively). In the bootstrap
samples, these were the most frequently
chosen models. These variables were also
chosen by the Cox modeling.
Clinical risk score
Clinicalriskscoreswerederived(Table3)
from the above equations. These scores
showed a good ﬁt (Hosmer-Lemeshow
P	0.8and0.9inmenandwomen,respec-
tively), and the discrimination was similar
tothemoreexactequationwithcontinuous
values of waist circumference.
The receiver operating characteristic
(ROC) curves for the clinical equation
and for the simpliﬁed clinical score are
shown for men and women (Fig. 1A); the
DESIR scores with three variables had
AROC values slightly higher than for the
ﬁve-variable FINDRISC score. The score
predicted diabetes in the two French co-
horts, with the AROCs similar to those
from DESIR (online appendix Fig. 1).
Biologic predictors of incident
diabetes
Fasting glucose was by far the factor most
predictive of incident diabetes, with no
difference in its effect between men and
women (P for interaction 	 0.1) (Table
1). Predictive factors differing between
sexes were triglycerides and HDL choles-
terol—both had a slightly stronger rela-
tion in women (P for sex interaction 	
0.006 and 0.008, respectively).
Clinical  biological predictors of
incident diabetes
Fasting glucose (including its squared
term) was the most predictive of all fac-
tors. After adjustment for fasting glucose,
waist circumference was more predictive
than BMI in men, but BMI was more pre-
dictive than waist in women (Table 2). In
men, the predicting equation included
fasting glucose, smoking status, waist cir-
cumference, and GGT and in women in-
cluded fasting glucose, BMI, diabetes in
the family, and triglycerides. The same
variables were chosen by Cox modeling
with ﬁve predictive variables. Our (clini-
cal  biological) equation was simpler
than the Stern equation with only four
variables and discriminated incident dia-
betic individuals similarly (Fig. 1B).
Genetic polymorphisms as
predictors of incident diabetes
None of the four polymorphisms was sig-
niﬁcantly related to incident diabetes in
either men or women, using either the
three genotypes or recessive, dominant,
or additive models of inheritance (online
appendix Table). There was no interac-
tion with sex, and combining men and
women, TCF7L2 and IL6 were signiﬁ-
cantly related with incident diabetes us-
ing additive models (P  0.01 and 0.03,
respectively). In comparison with indi-
viduals with no deleterious alleles, those
with four deleterious alleles had an OR of
incident diabetes of 3.60 (95% CI 1.09–
11.9) in men and 3.22 (0.62–16.5) in
women.Thenumberofdeleteriousalleles
was associated with incident diabetes in
both men and women (P  0.008 and
0.03, respectively) (Table 1). Including
the total number of deleterious alleles in
the above-determined (clinical  biolog-
ical) equations, models showed an ade-
quate ﬁt but little changed the AROC
(Table 2).
CONCLUSIONS — Both the clinical
and the (clinical  biological) equations
areabletopredictdiabetesincidenceover
a 9-year follow-up, with different vari-
ables in the equations for men and
women.Agewasnotselectedinanyofthe
equations, but age is highly correlated
withadiposity,hypertension,andglucose
Table 3—A clinical diabetes risk score of 5
confers a >30% chance of diabetes in the fol-
lowing 9 years: the DESIR study
Scores to
sum
Men
Waist circumference (cm)
80 0
80–89 1
90–99 2
100 3
Current smoker: yes 1
Hypertension: yes* 1
AROC statistic 0.713
Hosmer-Lemeshow ﬁt test P 	 0.8
Women
Waist circumference (cm)
70 0
70–79 1
80–89 2
90 3
Diabetes in the family: yes 1
Hypertension: yes* 1
AROC statistic 0.827
Hosmer-Lemeshow ﬁt test P 	 0.9
*Systolic/diastolic blood pressure 140/90 mmHg
or medication for hypertension.
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tions. Age was included in the equations
of many (3,5,8–10) but not all (7) of the
other published studies of risk equations.
Polymorphisms added little to these
scores. As expected, the equations de-
rived on our population performed
slightly better than those derived in other
populations.Theclinicalscoreperformed
well on two other French cohorts.
Our diabetes risk score based on clin-
icaldatahastheadvantagethatitissimple
andrequiresonlythreeparameters.Given
alargerpopulationandahigherincidence
of diabetes, other parameters might have
been included in the equations, but the
discrimination and model ﬁt may not be
greatly improved. BMI and waist circum-
ference had similarly predictive values in
both men and women; once one was in-
cluded, the other no longer entered the
model.Similarcommentscanbemadefor
GGT and ALT.
In contrast to other scores, we have
studied men and women separately and
foundthatthepredictiveequationsdiffer.
In both sexes, waist circumference was
the clinical factor most related to incident
diabetes; the next most predictive factor
in men was smoking, which was more
common in men than women; and in
women only, diabetes in the family was a
predictive factor. Hypertension was pre-
dictive of diabetes in both sexes, a factor
often present before diabetes (17). Smok-
ing is recognized as a risk factor for dia-
betes, with a higher risk for the heavy
smokers in comparison with the lighter
and former smokers (18). Our observa-
tion that more diabetic women than men
have diabetes in the family is probably
due to women being more aware of their
familyhistoryofdiabetes.Inthemultivar-
iate equations, physical activity was not
predictive—this could be because of its
negativecorrelationwithwaistcircumfer-
ence and hypertension and perhaps be-
cause our questions on self-reported
physical activity were not sufﬁciently
precise, in comparison with other data
such as waist circumference and hyper-
tension. Other studies have indeed
included physical activity in their mul-
tivariate equations (3,7,8).
The overriding biological factor pre-
dictive of diabetes was the baseline glu-
cose level. In the (clinical  biological)
equation in men, the GGT also entered
the equation and in women the triglycer-
ides concentration entered. We have al-
ready shown that GGT is predictive of
incident diabetes in this cohort for both
sexes (19), and others have shown that
triglycerides are predictive (5,10).
The polymorphisms studied pro-
vided little toward predicting diabetes:
for the 1,655 men and 1,740 women
with these data available, the Hosmer-
Lemeshow tests showed a poorer ﬁt for
men when the genetic data were included
but identical AROCs. Of note, in women,
the coefﬁcient for the parameter of diabetes
in the family was only reduced from 0.80
to 0.75 when genetic parameters were in-
cluded, indicating that other possible ge-
netic factors are involved. A large panel of
SNPs may be needed to outperform even
simple clinical parameters.
One of the limitations is that we have
not been able to include the 2-h glucose
concentration in our deﬁnition of diabe-
tes—inFrance,screeningofdiabeteswith
Figure 1—ROC curves and AROC statistics in men and women for the DESIR French clinical
equation, the French clinical risk score, and the FINDRISC clinical score (3) (A) and for DESIR
(clinical  biological) (B). French risk equation and Stern risk equation (9).
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therefore appropriate in the local situa-
tion. A further limitation is that the score
is only for people between 30 and 65
years of age.
The simplest clinical parameter for
identifying those at risk of diabetes is ad-
iposity, and taken alone, either waist cir-
cumference or BMI did equally well in
predictinglaterdiabetesduringthe9-year
follow-up. The addition of hypertension,
smoking in men, and triglycerides in
women provides a clinical score that dis-
criminates well.
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